Early detection of sepsis
First Claim
Patent Images
33-1. The method of claim 1, wherein said plurality of markers comprises markers selected from the group consisting of CD11b, CD64, HLA-DR, an interleukin protein, a tumor necrosis factor receptor, C-reactive protein, and procalcitonin.
0 Assignments
0 Petitions
Accused Products
Abstract
Diagnostic methods, systems, and kits for identifying patients with systemic inflammatory response syndrome who are likely to progress to sepsis.
-
Citations
60 Claims
-
33-1. The method of claim 1, wherein said plurality of markers comprises markers selected from the group consisting of CD11b, CD64, HLA-DR, an interleukin protein, a tumor necrosis factor receptor, C-reactive protein, and procalcitonin.
-
46. A method of detecting early sepsis in a patient, wherein said method comprising the steps of:
-
a) monitoring expression of markers comprising neutrophil-associated CD11b, neutrophil-associated CD64, and monocyte-associated HLA-DR over a period of time;
b) independently deriving marker statistics comprising a maximum of said neutrophil-associated CD11b expression, a maximum of said neutrophil-associated CD64 expression, and minimum of said monocyte-associated HLA-DR expression; and
c) applying a decision rule to the marker statistics from step (b) to detect early sepsis in said patient. - View Dependent Claims (47, 48, 60)
-
Specification